Changing the Practice of Medicine
Popular
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
- MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
CME/CE
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- MinuteCE®
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
2.00 credits 13 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
- CME/CE Broadcast Replay
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
1.00 creditRobert D. Suh, MD
Ashwin Basavaraj, MD
Mary Salvatore, MD, MBA
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD
Clinical Practice
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Chan Y. Cheah, MBBS
Alessandra Tedeschi, MD
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Programs
Florence Odufalu, MD
Ugo Iroku, MD, MHS
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
Florence Odufalu, MD
David T. Rubin, MD
Ugo Iroku, MD, MHS
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD